© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 27, 2016
Treatment with fixed-dos combination sofosbuvir/velpatasvir yielded significant improvements in patient-reported outcomes.
Filgotinib is the first oral, JAK1-selective inhibitor showing efficacy in moderate-to-severe Crohn's disease patients.
Risankizumab is a humanized monoclonal antibody that selectively inhibits IL-23 through specific targeting of the IL-23 p19 subunit.
May 25, 2016
Researchers reported that SVR12 rates in real-world, post-transplant genotype 1 HCV patients treated with ledipasvir-sofosbuvir, with or without ribavirin, is 98% across regimens and various characteristics.
Greater Baseline Retinal Nonperfusion Linked to Worsening Diabetic Retinopathy
John J. Miller, MD: A New Era For Psychiatric Medications
Aluminum Exposure Induces Cytokine Secretion in Crohn’s Disease Colons